In 353 adults randomised to a fourth dose of bivalent mRNA (Moderna) or protein (Novavax) COVID-19 vaccine, anti-spike IgG was higher with Moderna at 6 and 12 months (GMR 1.59 and 1.34), with no T-cell difference. Post hoc infection rates were 43.0% vs 47.0%.
Secondary analysisn = 353
Mazarakis et al. Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia